Lymphocyte blastogenic response to human thyroglobulin in Graves' disease, Hashimoto's thyroiditis, and metastatic thyroid cancer.
In view of the past contradictory reports concerning in vitro lymphocyte transformation induced by human thyroglobulin (Tg) in thyroid diseases, the present study was undertaken to re-examine the response using improved methods in cell separation, culture, and cell harvesting. It has been found that the optimal dose level of Tg for maximal blastogenesis in culture differs from patient to patient. Consequently, it is inappropriate to use a single dose level of Tg for evaluation of the blastogenesis in study groups. By using serial Tg dose levels of 0.5 through 30 micrograms/ml in cultures, it was found that that incidence of positive responders in Graves' disease was 69.2%, in Hashimoto's thyroiditis 71.4%, and in healthy controls 9.1%. Metastatic thyroid cancer patients responded in a 50% incidence. All of the positive responders in the cancer group had elevated Tg levels, but no anti-Tg antibody in their sera.
D000230:Adenocarcinoma / Q000276:immunology / Q000556:secondary*; D000328:Adult; D000906:Antibodies / Q000032:analysis; D002478:Cells, Cultured; D005260:Female; D006111:Graves Disease / Q000276:immunology*; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D013954:Thyroglobulin / Q000276:immunology*; D013964:Thyroid Neoplasms / Q000276:immunology*; D013967:Thyroiditis, Autoimmune / Q000276:immunology*
D000906:Antibodies; D013954:Thyroglobulin